Overview

  • Product name
  • Description
    Rabbit polyclonal to Plasminogen
  • Host species
    Rabbit
  • Tested applications
    Suitable for: WB, IHC-P, ICC/IFmore details
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    Recombinant fragment corresponding to a region within amino acids 84-434 of Human Plasminogen (Uniprot ID: P00747).

  • Positive control
    • Jurkat, Raji, K562, BCL1, PC12 and Rat2 whole cell lysates, HeLa cells, Human C2C12 xenograft tissue and hepatoma tissue

Properties

Applications

Our Abpromise guarantee covers the use of ab154560 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/500 - 1/3000. Predicted molecular weight: 90 kDa.
IHC-P 1/100 - 1/1000.
ICC/IF 1/100 - 1/1000.

Target

  • Function
    Plasmin dissolves the fibrin of blood clots and acts as a proteolytic factor in a variety of other processes including embryonic development, tissue remodeling, tumor invasion, and inflammation. In ovulation, weakens the walls of the Graafian follicle. It activates the urokinase-type plasminogen activator, collagenases and several complement zymogens, such as C1 and C5. Cleavage of fibronectin and laminin leads to cell detachment and apoptosis. Also cleaves fibrin, thrombospondin and von Willebrand factor. Its role in tissue remodeling and tumor invasion may be modulated by CSPG4. Binds to cells.
    Angiostatin is an angiogenesis inhibitor that blocks neovascularization and growth of experimental primary and metastatic tumors in vivo.
  • Tissue specificity
    Present in plasma and many other extracellular fluids. It is synthesized in the liver.
  • Involvement in disease
    Defects in PLG are a cause of susceptibility to thrombosis (THR) [MIM:188050]. It is a multifactorial disorder of hemostasis characterized by abnormal platelet aggregation in response to various agents and recurrent thrombi formation.
    Defects in PLG are the cause of plasminogen deficiency (PLGD) [MIM:217090]. PLGD is characterized by decreased serum plasminogen activity. Two forms of the disorder are distinguished: type 1 deficiency is additionally characterized by decreased plasminogen antigen levels and clinical symptoms, whereas type 2 deficiency, also known as dysplasminogenemia, is characterized by normal, or slightly reduced antigen levels, and absence of clinical manifestations. Plasminogen deficiency type 1 results in markedly impaired extracellular fibrinolysis and chronic mucosal pseudomembranous lesions due to subepithelial fibrin deposition and inflammation. The most common clinical manifestation of type 1 deficiency is ligneous conjunctivitis in which pseudomembranes formation on the palpebral surfaces of the eye progresses to white, yellow-white, or red thick masses with a wood-like consistency that replace the normal mucosa.
  • Sequence similarities
    Belongs to the peptidase S1 family. Plasminogen subfamily.
    Contains 5 kringle domains.
    Contains 1 PAN domain.
    Contains 1 peptidase S1 domain.
  • Domain
    Kringle domains mediate interaction with CSPG4.
  • Post-translational
    modifications
    N-linked glycan contains N-acetyllactosamine and sialic acid. O-linked glycans consist of Gal-GalNAc disaccharide modified with up to 2 sialic acid residues (microheterogeneity).
    In the presence of the inhibitor, the activation involves only cleavage after Arg-580, yielding two chains held together by two disulfide bonds. In the absence of the inhibitor, the activation involves additionally the removal of the activation peptide.
  • Cellular localization
    Secreted. Locates to the cell surface where it is proteolytically cleaved to produce the active plasmin. Interaction with HRG tethers it to the cell surface.
  • Information by UniProt
  • Database links
  • Form
    Cleaved into the following 5 chains: 1.Plasmin heavy chain A2.Activation peptide3.Angiostatin4.Plasmin heavy chain A, short form5. Plasmin light chain B
  • Alternative names
    • Plasmin antibody
    • Plasmin heavy chain A antibody
    • Plasmin light chain B antibody
    • Plasminogen antibody
    • PLG antibody
    • PLMN_HUMAN antibody
    see all

Images

  • Anti-Plasminogen antibody (ab154560) at 1/1000 dilution + BCL1 whole cell lysate at 30 µg

    Predicted band size: 90 kDa



    7.5% SDS PAGE
  • All lanes : Anti-Plasminogen antibody (ab154560) at 1/1000 dilution

    Lane 1 : Jurkat whole cell lysate
    Lane 2 : Raji whole cell lysate
    Lane 3 : K562 whole cell lysate

    Lysates/proteins at 30 µg per lane.

    Predicted band size: 90 kDa



    7.5% SDS PAGE
  • Immunohistochemical analysis of paraffin-embedded Rat prostate tissue, labeling Plasminogen using ab154560 at a 1/500 dilution.

  • All lanes : Anti-Plasminogen antibody (ab154560) at 1/1000 dilution

    Lane 1 : PC12 whole cell lysate
    Lane 2 : Rat2 whole cell lysate

    Lysates/proteins at 30 µg per lane.

    Predicted band size: 90 kDa



    7.5% SDS PAGE
  • Immunofluorescence analysis of methanol-fixed HeLa cells, labeling Plasminogen using ab154560 at a 1/500 dilution. Lower image is costained with Hoechst 33342.
  • Immunohistochemical analysis of paraffin-embedded Human C2C12 xenograft, labeling Plasminogen using ab154560 at a 1/500 dilution.
  • Immunohistochemical analysis of paraffin-embedded Hepatoma tissue, labeling Plasminogen using ab154560 at a 1/500 dilution.

References

This product has been referenced in:
See all 3 Publications for this product

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab154560.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up